Roivant Sciences (ROIV) Other Non-Current Assets (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Other Non-Current Assets came in at $40.9 million in Q1 2026, up 24.52% YoY from $32.9 million in Q1 2025, and up 18.38% on a QoQ basis from $34.6 million in Q4 2025.
Roivant Sciences (ROIV) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Other Non-Current Assets data on file, last reported at $40.9 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 24.52% year-over-year to $40.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.9 million (up 24.52% YoY) and the FY2026 annual result came in at $40.9 million, up 24.52% from the prior year.
- Other Non-Current Assets rose to $40.9 million in Q1 2026, from $34.6 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $145.9 million in Q1 2024 to a low of $11.9 million in Q3 2022.
- A 5-year average of $41.6 million and a median of $34.6 million in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 417.27% — and 2025, when it plunged 77.47%.
- Tracing ROIV's Other Non-Current Assets over 5 years: stood at $46.2 million in 2022, then grew by 1.35% to $46.8 million in 2023, then retreated by 27.68% to $33.9 million in 2024, then advanced by 2.02% to $34.6 million in 2025, then increased by 18.38% to $40.9 million in 2026.
- The last three Other Non-Current Assets figures came in at $40.9 million (Q1 2026), $34.6 million (Q4 2025), and $27.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 29.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.59 Mn |
| Mar 31, 2026 | 40.92 Mn |
| Dec 31, 2025 | 34.56 Mn |
| Sep 30, 2025 | 27.83 Mn |
| Jun 30, 2025 | 31.09 Mn |
| Mar 31, 2025 | 32.86 Mn |
| Dec 31, 2024 | 33.88 Mn |
| Sep 30, 2024 | 36.90 Mn |
| Jun 30, 2024 | 32.81 Mn |
| Mar 31, 2024 | 145.88 Mn |
| Dec 31, 2023 | 46.85 Mn |
| Sep 30, 2023 | 49.80 Mn |
| Jun 30, 2023 | 46.31 Mn |
| Mar 31, 2023 | 49.48 Mn |
| Dec 31, 2022 | 46.22 Mn |
| Sep 30, 2022 | 11.87 Mn |
| Jun 30, 2022 | 14.25 Mn |
| Mar 31, 2022 | 25.82 Mn |
| Dec 31, 2021 | 8.94 Mn |
| Sep 30, 2021 | 21.34 Mn |